Latest News
Connected Thinking
Leading Voices
Latest News
Addressing Disparities in Cancer: What Industry and Clinicians Can Do to Collaborate Effectively
As key players in the oncology community, industry and clinicians have the power to make tangible progress on key aspects on disparities, according to panelists at Survivornet’s 2022 Close the Gap conference.
Learn More‘This is a Period of Rapid Progress:’ Dr. Giovanni Caforio of Bristol-Myers Squibb on the Revolution in Immunotherapy Drugs for Treating Advanced Cancers
Every once in a while, we think there’s some value in giving the SN Connect audience a little taste of some very key players in the oncology system. A while back, SurvivorNet had the chance to sit down with Dr. Giovanni Caforio, chairman and CEO of Bristol-Myers Squibb (BMS).
Learn MoreASCO: Study Finds Ibrutinib Can Improve Outcomes In Some Newly Diagnosed Patients With Mantle Cell Lymphoma
The trial showed improvement in progression-free survival for patients with newly diagnosed mantle cell lymphoma.
Learn MoreASCO: New Study Provides Hope For Patients With HER2 ‘Low’ Breast Cancer
HER2 “low” may become a new commonly classified subtype of breast cancer.
Learn MoreASCO: Updated Guidelines on Biomarkers for Early-Stage Breast Cancer
The new guidelines now recommend the use of Breast Cancer Index (BCI) to assess the risk of breast cancer recurrence in some patients.
Learn MoreASCO: Study Indicates Panitumumab Works Best For Patients With One Type Of Metastatic Colorectal Cancer
A new trial is the first to compare the effectiveness of different targeted drug therapies as part of chemo treatments for a certain kind of metastatic colorectal cancer (left sided).
Learn MoreTreating Multiple Myeloma in the Second Line: Which Option Should You Choose?
After first-line multiple myeloma treatment, which strategy is best for second-line therapy?
Learn MoreBispecific Antibodies Challenge CAR T-Cell Therapy as Multiple Myeloma Treatment Contender
The latest buzzword in multiple myeloma is bispecifics. This off-the-shelf treatment is proving to be an attractive option for patients who can't wait for CAR T-cell therapy.
Learn More